Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data

While adjuvant abemaciclib is approved for N+, high-risk, HR-positive, HER2-negative EBC, utilization remains suboptimal in eligible patients, despite high recurrence and mortality risks similar to eTNBC. These data indicate the need for education about risk identification and implementation of optimal therapy.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-01-19
DOI
https://doi.org/10.1016/j.esmoop.2025.106021
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
36.44

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data

AM Liepa, D. He, J. Roose, S. Sammons et al.
1 citations
ESMO Open
Advanced Breast Cancer Therapies
36.44
article

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data

AM Liepa, D. He, J. Roose, S. Sammons, W. Gathirua-Mwangi, S.R.D. Johnston, J. Cortes, P. Neven, J. O’Shaughnessy, Z.L. Cui, A. Sandoval-Leon, K. Moreira, H.S. Rugo, B.R. Grimes, S.M. Tolaney
article en
1 citations

Abstract

While adjuvant abemaciclib is approved for N+, high-risk, HR-positive, HER2-negative EBC, utilization remains suboptimal in eligible patients, despite high recurrence and mortality risks similar to eTNBC. These data indicate the need for education about risk identification and implementation of optimal therapy.

ESMO OpenVol. 11(2)
Baptist Hospital of Miami (US), Royal Marsden NHS Foundation Trust (GB), Eli Lilly (United States) (US), Texas Oncology (US), Baylor University Medical Center (US), Baptist Health South Florida (US), Syneos Health (United States) (US), City of Hope (US), Dana-Farber Cancer Institute (US), Flatiron Health (United States) (US), Universidad Europea de Madrid (ES), KU Leuven (BE)
Eli Lilly and Company, AstraZeneca
Good health and well-being
Openalex Percentile: Top 2%
Advanced Breast Cancer Therapies
36.44
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data — AM Liepa, D. He, et al. · ESMO Open (2026) | TGRS Research Map | TGRS